Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on December 30, 2020, covering events occurring on December 27, 2020. The filing details the execution of amended and restated employment agreements with six executive officers, effective January 1, 2021.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and severance provisions.
Material Changes
The primary material change is the revision of employment terms for the following executives: Joseph Ciaffoni (CEO), Paul Brannelly (CFO), Scott Dreyer (CCO), Alison B. Fleming (CTO), Shirley Kuhlmann (General Counsel), and Richard Malamut (CMO). The new agreements supersede existing contracts, specifically updating severance benefits and restrictive covenants.
Guidance, Outlook, and Management Commentary
The filing outlines specific severance triggers and benefits:
- Termination without Cause or Resignation with Good Reason:
- Mr. Ciaffoni receives 18 months of severance; other executives receive 12 months.
- Benefits include continued base salary, payment of prior year bonuses, and a cash severance equal to the target annual bonus (150% for Mr. Ciaffoni).
- Time-based unvested equity vests immediately over the severance period.
- COBRA premiums are waived during the severance period.
- Change in Control followed by Termination (within 12 months):
- All time-based unvested equity vests immediately.
- Lump sum payment of 18 months' base salary (24 months for Mr. Ciaffoni).
- Lump sum payment of 1.5x target annual bonus (2x for Mr. Ciaffoni).
- COBRA premiums waived for 18 months (24 months for Mr. Ciaffoni).
- Restrictive Covenants: Executives are subject to customary covenants for 12 months post-termination (18 months for Mr. Ciaffoni).
Investor Verification Checklist
- Review the full text of the Amended & Restated Employment Agreements filed as Exhibits 10.1 through 10.6 for complete legal definitions of "Cause," "Good Reason," and "Change in Control."
- Verify the specific base salary and target bonus percentages for each executive to calculate potential severance liabilities.
- Assess the impact of immediate equity vesting on potential dilution in the event of a Change in Control.
- Confirm the duration of restrictive covenants to understand potential limitations on executive mobility post-employment.